Upgrade to SI Premium - Free Trial

BioLineRx (BLRX)

3.13 -0.10 (3.10%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/14/26 *Est.)

Latest Headlines

BioLineRx (BLRX) Reports In-Line Q1 EPS May 27, 2026 7:38 AM - StreetInsider Form 6-K BioLineRx Ltd. For: May 27 May 27, 2026 7:20 AM - SEC Filing BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update May 27, 2026 7:00 AM - PR NewsWire BioLineRx and Hemispherian to present GLIX1 data at ASCO 2026 May 22, 2026 7:01 AM - StreetInsider Form 6-K BioLineRx Ltd. For: May 22 May 22, 2026 7:00 AM - SEC Filing BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting May 22, 2026 7:00 AM - PR NewsWire BioLineRx to Report First Quarter 2026 Results on May 27, 2026 May 20, 2026 7:01 AM - PR NewsWire Form 6-K BioLineRx Ltd. For: May 19 May 19, 2026 7:07 AM - SEC Filing BioLineRx reports positive preclinical data for GLIX1 in brain cancer May 19, 2026 7:02 AM - StreetInsider BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Pat May 19, 2026 7:00 AM - PR NewsWire Form 6-K BioLineRx Ltd. For: Apr 28 April 28, 2026 7:16 AM - SEC Filing BioLineRx doses first patient in glioblastoma trial with GLIX1 drug April 28, 2026 7:00 AM - StreetInsider BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) April 28, 2026 7:00 AM - PR NewsWire Form 3 BioLineRx Ltd. For: Mar 18 Filed by: Yan Shaoyu April 10, 2026 4:01 PM - SEC Filing Hemispherian begins clinical trial of GLIX1 for glioblastoma treatment April 8, 2026 2:30 AM - StreetInsider Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma April 8, 2026 2:30 AM - BizWire Form 3 BioLineRx Ltd. For: Mar 18 Filed by: PANEM SANDRA March 31, 2026 4:04 PM - SEC Filing Form 3 BioLineRx Ltd. For: Mar 18 Filed by: Hofstein Raphael March 31, 2026 4:03 PM - SEC Filing Form 3 BioLineRx Ltd. For: Mar 18 Filed by: Dar Rami March 31, 2026 4:02 PM - SEC Filing Form 3 BioLineRx Ltd. For: Mar 18 Filed by: Molcho Avraham March 31, 2026 4:01 PM - SEC Filing Form 3 BioLineRx Ltd. For: Mar 18 Filed by: Cohen Gal Avraham March 30, 2026 6:02 PM - SEC Filing Form 3 BioLineRx Ltd. For: Mar 18 Filed by: Schwartz Aharon March 30, 2026 6:02 PM - SEC Filing Form 20-F/A BioLineRx Ltd. For: Dec 31 March 27, 2026 4:33 PM - SEC Filing Form 3 BioLineRx Ltd. For: Mar 18 Filed by: Serlin Philip A March 27, 2026 4:06 PM - SEC Filing Form 6-K BioLineRx Ltd. For: Mar 26 March 26, 2026 7:13 AM - SEC Filing BioLineRx begins phase 1/2a trial of GLIX1 for glioblastoma treatment March 26, 2026 7:00 AM - StreetInsider BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) March 26, 2026 7:00 AM - PR NewsWire Form 6-K BioLineRx Ltd. For: Mar 23 March 23, 2026 7:14 AM - SEC Filing Form 20-F BioLineRx Ltd. For: Dec 31 March 23, 2026 7:10 AM - SEC Filing BioLineRx Reports 2025 Financial Results and Provides Corporate Update March 23, 2026 7:00 AM - PR NewsWire Form 3 BioLineRx Ltd. For: Mar 18 Filed by: Zeevi Mali March 18, 2026 5:27 PM - SEC Filing Form 3 BioLineRx Ltd. For: Mar 18 Filed by: BORMANN-KENNEDY BARBARA-JEAN ANNE March 18, 2026 5:23 PM - SEC Filing BioLineRx to Report 2025 Annual Results on March 23, 2026 March 16, 2026 7:00 AM - PR NewsWire Full Article List